Advertisement

Annals of Surgical Oncology

, Volume 10, Issue 8, pp 898–902 | Cite as

Follow-Up Surveillance for Recurrence After Curative Gastric Cancer Surgery Lacks Survival Benefit

  • Yasuhiro Kodera
  • Seiji Ito
  • Yoshitaka Yamamura
  • Yoshinari Mochizuki
  • Michitaka Fujiwara
  • Kenji Hibi
  • Katsuki Ito
  • Seiji Akiyama
  • Akimasa Nakao
Original Articles

Abstract

Background: Although routine follow-up to detect asymptomatic recurrence after surgery for gastric cancer is recommended, the effect of such reassessment on survival has not been evaluated.

Methods: Clinical records of patients developing recurrent disease after potentially curative resection between 1985 and 1996 were retrieved. Among these patients, 197 were in our follow-up program. We analyzed survival in these patients according to the presence or absence of cancer-related symptoms when recurrent disease was diagnosed.

Results: Of all patients with recurrent disease, 50% were diagnosed within 1 year and 75% within 2 years of surgery. Asymptomatic recurrence, detected in 88 patients (45%), frequently represented distant metastasis. Although early detection significantly improved survival after detection of recurrent disease, disease-free survival for this subset was shorter. Thus, no significant difference in overall survival was observed.

Conclusions: Early detection of asymptomatic gastric cancer recurrence did not improve overall survival of patients with recurrence after curative resection. Until development of more effective treatment for this disease, close follow-up may offer no survival benefit.

Key Words

Cancer recurrence Follow-up Gastrectomy Curative resection Gastric carcinoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Gunderson LL, Donohue JH, Burch PA. Stomach Abeloff MD, Armitage JO, Lichter AS Eds. Clinical Oncology. New York:: Churchill Livingstone, 1995: 1209–41.Google Scholar
  2. 2.
    Boehner H, Zimmer T, Hopfenmueller W, Berger G, Buhr HJ. Detection and prognosis of recurrent gastric cancer—is routine follow-up after gastrectomy worthwhile? Hepatogastroenterology 2000;47:1489–94.Google Scholar
  3. 3.
    NCCN practice guidelines for upper gastrointestinal carcinomas. National Comprehensive Cancer Network. Oncology (Huntingt) 1998;12:179–223.Google Scholar
  4. 4.
    Sobin, LHWittekind, C eds. 1997TNM Classification of Malignant Tumours5th ed.WileyNew YorkGoogle Scholar
  5. 5.
    Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 1993;72:37–41.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163–8.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Pyrhoenen S, Kuitunen T, Nyandoto P, Kouri M. Randomized comparison of 5-fluorouracil, epidoxorubicin, and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587–91.CrossRefGoogle Scholar
  8. 8.
    Boku N, Ohtsu A, Shimada Y, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999;17:319–23.CrossRefPubMedGoogle Scholar
  9. 9.
    Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 in advanced gastric cancer patients. Eur J Cancer 1998;34:1715–20.CrossRefPubMedGoogle Scholar
  10. 10.
    Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000;87:236–42.CrossRefPubMedGoogle Scholar
  11. 11.
    Howell JD, Wotherspoon H, Leen E, Cooke TC, McArdle CS. Evaluation of a follow-up programme after curative resection for colorectal cancer. Br J Cancer 1999;79:308–10.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Yasui K, Hirai T, Kato T, et al. A new macroscopic classification predicts prognosis for patients with liver metastases from colorectal cancer. Ann Surg 1997;226:582–6.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Saiura A, Umekita N, Inoue S, et al. Clinicopathological features and outcome of hepatic resection for liver metastasis from gastric cancer. Hepatogastroenterology 2002;49:1062–5.PubMedGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 2003

Authors and Affiliations

  • Yasuhiro Kodera
    • 1
    • 3
  • Seiji Ito
    • 2
  • Yoshitaka Yamamura
    • 2
  • Yoshinari Mochizuki
    • 2
  • Michitaka Fujiwara
    • 1
  • Kenji Hibi
    • 1
  • Katsuki Ito
    • 1
  • Seiji Akiyama
    • 1
  • Akimasa Nakao
    • 1
  1. 1.Department of Surgery IINagoya University School of MedicineAichiJapan
  2. 2.Department of Gastroenterological SurgeryAichi Cancer CenterAichiJapan
  3. 3.Department of Surgery IINagoya University School of MedicineAichiJapan

Personalised recommendations